Active, Not Recruiting
Long-Term Safety and Efficacy Study of BMS-986165 in Participants With Systemic Lupus Erythematosus - IM011-074
Aggiornato:
19 dicembre, 2023
|
ClinicalTrials.gov.
Fase
Sesso
Fascia d'età
Active, Not Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Completion of SLE Study (NCT03252587) through the protocol-required treatment period, and currently receiving blinded study drug - Women of childbearing potential (WOCBP) must have a negative urine pregnancy test and must agree to use correctly a highly effective method(s) of contraception for the duration of treatment with study drug Exclusion Criteria: - Any disease or medical condition that, in the opinion of the investigator, would make the subject unsuitable for this study, would interfere with the interpretation of subject safety or study results, or considered unsuitable by the investigator for any other reason - Evidence of active tuberculosis (TB) Other protocol defined inclusion/exclusion criteria could apply
Ti consigliamo vivamente di contattare BMS per segnalare gli effetti collaterali (eventi avversi)
Qui vengono definiti gli effetti collaterali (eventi avversi) e altri eventi da segnalare
Segnala effetti collaterali (eventi avversi) o reclami sulla qualità del prodotto: informazioni mediche